12:00 AM
 | 
Dec 16, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Revlimid lenalidomide: Additional Phase III data

Additional data from the open-label, international Phase III FIRST (MM-020/IFM 07-01) trial in 1,623 patients aged 65 and older with newly diagnosed MM who are ineligible for autologous stem cell transplantation (ASCT) showed that continuous oral Revlimid plus low-dose dexamethasone until disease progression led to a median PFS, the primary endpoint, of 25.5 months vs. 21.2 months for a combination of melphalan, prednisone and thalidomide for 72 weeks at a median follow-up of 37 months (HR=0.72, p=0.00006). Continuous Revlimid plus low-dose dexamethasone until disease progression also...

Read the full 409 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >